Albumin Paclitaxel

Phase 3Small molecule

Albumin Paclitaxel is one of 330 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

329

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaEnrolling by invitation

AdenocarcinomaActive, not recruiting

Efficacy and SafetyNot yet recruiting

HR+/HER2- Breast CancerRecruiting

First-Line TreatmentRecruiting

Neoadjuvant TherapyNot yet recruiting

Adjuvant TherapyRecruiting

PaclitaxelRecruiting

Pancreatic NeoplasmRecruiting

Esophageal CarcinomaNot yet recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Enrolling by invitation

AdenocarcinomaPreclinical

Active, not recruiting

Efficacy and SafetyPreclinical

Not yet recruiting

HR+/HER2- Breast CancerPhase 2

Recruiting

First-Line TreatmentPhase 1

Recruiting

Neoadjuvant TherapyPhase 2

Not yet recruiting

Adjuvant TherapyPhase 2

Recruiting

PaclitaxelPhase 2

Recruiting

Pancreatic NeoplasmPhase 2

Recruiting

Esophageal CarcinomaPhase 2

Not yet recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 3

6 2

Albumin Paclitaxel

CChipscreen Biosciences, Ltd.

Phase 3

3 3

Carboplatin Plus Paclitaxel

Bayer

Phase 3

2 4

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Adjuvant Therapy

NCT06081673

Phase 2Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT06492915

Phase 2Recruiting

Pancreatic Neoplasm

NCT06767813

N/ANot yet recruiting

Efficacy and Safety

NCT06603974

Phase 2/3Recruiting

Pathological Response

NCT05125055

Phase 2Active, not recruiting

Lung Cancer

NCT04836728

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06391008·44 enrolled

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT04646837·20 enrolled

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT06704620·430 enrolled

Esophageal Carcinoma2 trials

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Unknown status·—·Phase 1/2·NCT05777707·89 enrolled

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT05996484·25 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Recruiting·FFuzhou General Hospital·Phase 2·NCT05515315·93 enrolled

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Enrolling by invitation·PPeking University·Phase 2·NCT07312578·48 enrolled

Gastric Cancer2 trials

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Unknown status·RRuijin Hospital·Phase 2/3·NCT05002686·60 enrolled

A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences··NCT06417892·60 enrolled

Breast Cancer2 trials

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04681911·71 enrolled

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Unknown status·WWest China Hospital·Phase 1/2·NCT04152057·20 enrolled

20 more indications

Pancreatic Ductal Adenocarcinoma2 trials

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT07445295·558 enrolled

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 2·NCT06492915·42 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05344742·116 enrolled

Mucosal Melanoma1 trial

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

Completed·EEucure (Beijing) Biopharma Co., Ltd·Phase 2·NCT05420324·20 enrolled

Nasopharyngeal Carcinoma1 trial

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04282070·91 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruiting·XXijing Hospital·N/A·NCT06603974·48 enrolled

Lung Cancer1 trial

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04836728·156 enrolled

Neoadjuvant Therapy1 trial

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

Not yet recruiting·HHarbin Medical University·Phase 2·NCT06508229·65 enrolled

Adjuvant Therapy1 trial

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06081673·72 enrolled

Triple-Negative Breast Cancer1 trial

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05244993·42 enrolled

Neoadjuvant Treatment1 trial

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06927180·180 enrolled

Paclitaxel1 trial

Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

Recruiting·FFudan University·Phase 2·NCT06684327·100 enrolled

Pancreatic Neoplasm1 trial

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 2·NCT06767813·80 enrolled

First-line Treatment1 trial

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Recruiting·PPeking University Cancer Hospital & Institute·Phase 1·NCT06969612·21 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04922450·53 enrolled

Cervical Cancer1 trial

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04884906·40 enrolled

Chemotherapy1 trial

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04698941·40 enrolled

Brain Metastases1 trial

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Unknown status·GGuangdong Association of Clinical Trials·Phase 3·NCT04768075·200 enrolled

Oral Squamous Cell Carcinoma1 trial

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Recruiting·WWeijia Fang, MD·Phase 2·NCT05862168·30 enrolled

Pathological Response1 trial

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT05125055·80 enrolled

HR+/HER2- Breast Cancer1 trial

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06860529·357 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Albumin Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chipscreen Biosciences, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChipscreen Biosciences, Ltd.

Albumin Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Esophageal Carcinoma2 trials

Esophageal Squamous Cell Carcinoma2 trials

Gastric Cancer2 trials

Breast Cancer2 trials

Pancreatic Ductal Adenocarcinoma2 trials

Patients With Advanced Solid Tumors1 trial

Mucosal Melanoma1 trial

Nasopharyngeal Carcinoma1 trial

Efficacy and Safety1 trial

Lung Cancer1 trial

Neoadjuvant Therapy1 trial

Adjuvant Therapy1 trial

Triple-Negative Breast Cancer1 trial

Neoadjuvant Treatment1 trial

Paclitaxel1 trial

Pancreatic Neoplasm1 trial

First-line Treatment1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Cervical Cancer1 trial

Chemotherapy1 trial

Brain Metastases1 trial

Oral Squamous Cell Carcinoma1 trial

Pathological Response1 trial

HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News